Loading...
Not a good buy right now for an impatient investor. Price action and momentum indicators still lean bearish, Intellectia signals are absent, and the latest analyst update (BofA Underperform with a $14 PT) argues for more downside risk than upside at current ~$18.10. Better to wait rather than buy immediately.
Trend/momentum: Bearish-to-neutral. MACD histogram is -0.269 and negatively expanding, indicating downside momentum is still building rather than stabilizing. RSI(6) is ~28.4 (near oversold), which can support a short-term bounce, but it’s not a confirmed reversal signal by itself. Moving averages are converging, suggesting a potential transition phase, but not yet a clear uptrend. Key levels: Current price 18.10 is below the pivot 19.675 (bearish bias). Nearest support S1 is 17.616 (close—risk of a support test). If S1 breaks, next support is S2 at 16.344. Upside resistance levels are 21.734 (R1) and 23.006 (R2). Intellectia Proprietary Trading Signals: Intellectia Proprietary Trading Signals
Latest reported quarter: 2025/Q3. Growth/margins weakened: Revenue 262.0M (-5.68% YoY), Net Income 2.13M (-60.24% YoY), Gross Margin 20.98 (down ~20.89% YoY). EPS was 0.23 (+130% YoY), but the large net income decline and margin compression indicate underlying profitability pressure despite the EPS growth.
Recent trend: Net negative tilt. JPMorgan is Neutral with PT raised to $19 (from $17) in Dec 2025, but still cautious on 2026 fundamentals; earlier assumption coverage was Neutral with $17. The latest update is BofA cutting PT to $14 (from $15) and maintaining Underperform (Jan 2026), implying meaningful downside from the current price. Wall Street pros: Medium-term growth/ROE narrative and ‘reasonable’ valuation comments from JPM. Wall Street cons: Multiple firms cautious on 2026 homebuilder demand/supply and competitive conditions; BofA explicitly bearish with a PT well below market, suggesting limited near-term upside and higher downside risk.